Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGenixPharmaceucticals Corporation

GenixPharmaceucticals Corporation

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.02 CAD 0.00(0%)
Last update at 2026-11-03T14:30:00Z
Market Cap
1.22M

Momentum Score

…

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.02
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public filings for GenixPharmaceucticals Corporation (GENX.V) are limited and provide little detail on operations or products. Any long-term upside would depend on clinical progress, partnerships or successful financing, which may attract investors seeking early-stage biotech exposure.

Main risk is very limited disclosure and the sector's early-stage financing, execution and liquidity risks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.18M
Debt / Equity
-
ROE
-661.13%
Net Debt
1.00M
ROCE
10.80%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -0.34M -0.07M -4.40M -1.07M -1.65M
Net income -0.34M -0.07M -4.40M -1.07M -1.65M
Selling general administrative 0.11M 0.17M 0.28M 0.43M 1.12M
Gross profit 0.00M 0.00M 0.00M - -
Reconciled depreciation 0.00M 0.00M 0.55M 0.56M 0.54M
Ebit - - - -1.00M -1.61M
Ebitda - - - -0.50M -1.11M
Operating income -0.15M -0.24M -0.88M -1.03M -1.65M
Interest expense 0.17M 0.12M 0.05M 0.01M 0.00M
Interest income 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.17M -0.12M -0.05M -0.01M -0.00M
Total revenue 0.00M 0.00M 0.01M 0.00M 0.00M
Total operating expenses 0.15M 0.25M 0.89M 1.03M 1.65M
Cost of revenue 0.00M 0.00M 0.01M - -
Total other income expense net -0.01M 0.29M -3.46M -0.03M 0.00M
Net income from continuing ops -0.34M -0.07M -4.40M -1.07M -1.65M
Net income applicable to common shares - - - -1.07M -1.65M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 0.05M 0.05M 0.22M 4.25M 4.77M
Intangible assets 0.00M 0.01M 0.01M 4.01M 4.55M
Total liab 1.47M 1.23M 1.36M 1.05M 0.76M
Total stockholder equity -1.42M -1.18M -1.14M 3.20M 4.01M
Other current liab 0.25M 0.24M 0.58M 0.64M 0.66M
Common stock - - - 9.70M 9.70M
Capital stock 9.76M 9.70M 9.70M 9.70M 9.70M
Retained earnings -12.54M -12.20M -12.13M -7.74M -6.66M
Cash 0.04M 0.01M 0.01M 0.01M 0.14M
Total current liabilities 1.47M 1.23M 1.36M 1.05M 0.74M
Net debt 1.00M 0.80M 0.50M 0.17M -
Short long term debt 1.04M 0.82M 0.51M 0.18M 0.02M
Other stockholder equity - - - 1.23M 0.97M
Property plant equipment - - - 0.00M 0.03M
Total current assets 0.05M 0.04M 0.22M 0.24M 0.19M
Net tangible assets - - - -0.81M -0.53M
Net receivables 0.00M 0.01M 0.00M 0.02M 0.00M
Inventory - 0.00M 0.16M 0.17M 0.00M
Accounts payable 0.16M 0.15M 0.25M 0.21M 0.01M
Non current assets total 0.00M 0.01M 0.01M 4.01M 4.58M
Capital lease obligations - - 0.00M 0.00M 0.03M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments - - 0.00M -0.00M -
Change to liabilities - - - 0.18M -0.09M
Total cashflows from investing activities - - - -0.00M -0.00M
Net borrowings 0.06M 0.19M 0.28M 0.15M -0.01M
Total cash from financing activities 0.16M 0.19M 0.22M 0.09M -0.13M
Change to operating activities - - - -0.00M -0.03M
Net income -0.34M -0.07M -4.40M -1.07M -1.65M
Change in cash 0.03M -0.00M 0.00M -0.13M -0.56M
Begin period cash flow 0.01M 0.01M 0.01M 0.14M 0.70M
End period cash flow 0.04M 0.01M 0.01M 0.01M 0.14M
Total cash from operating activities -0.12M -0.19M -0.22M -0.22M -0.43M
Issuance of capital stock 0.10M - - - -
Depreciation 0.00M 0.00M 0.55M 0.56M 0.54M
Change to inventory 0.00M -0.00M 0.01M -0.17M -0.00M
Change to account receivables - - - -0.01M 0.00M
Other cashflows from financing activities - - - -0.05M -0.12M
Change to netincome - - - 0.30M 0.81M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.03M 0.03M 0.06M -0.01M -0.12M
Stock based compensation 0.00M 0.03M 0.06M 0.26M 0.81M
Other non cash items 0.17M 0.12M 0.05M 0.01M 0.00M
Free cash flow -0.12M -0.19M -0.22M -0.22M -0.43M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GENX
GenixPharmaceucticals Corporation		 -
-%		 0.02 - - 17418.86 1.04 32980.85 30.96
RX
Biosyent Inc.		 0.30
1.78%		 17.15 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.21
11.67%		 2.01 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
LSL
LSL Pharma Group Inc.		 0.01
1.64%		 0.31 20.75 - 1.88 1.89 2.85 10.19

Profile*

GenixPharmaceucticals Corporation

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9

604-609-6198

https://genixpharm.com

Name Title Year Born
Mr. Sina Salehi Pirooz CEO & Director NA
Mr. Mahmoud S. Aziz Pres & Director 1958
Mr. Wayne Kent Lee CA, CPA Chief Financial Officer 1968
Mr. Kevin James Bottomley Director of Corp. Devel. & Independent Director NA
Dr. Haofang Song Mang. NA
Ms. Monita Franziska Valeska Faris Company Sec. 1967
Mr. Mahmoud S. Aziz Chairman of the Board & President 1958
Mr. Kevin James Bottomley Director of Corporate Development & Independent Director 1979
Ms. Monita Franziska Valeska Faris Company Secretary 1967
Mr. Kevin James Bottomley Director of Corporate Development & Independent Director 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…